Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc. (LCTX) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
lctx · stock forecast · 5 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 5 Wall Street analysts in the past 3 months
Buy
5 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $1.25
Short-Term Price Prediction
BearAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $1.19 | ↓ 4.08% |
1-day model range: $1.18–$1.2. Peak: $1.2 (-4.08%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $1 | -43.8% |
| 2028 | $1 | -57.3% |
| 2029 | $0 | -63.0% |
| 2030 | $0 | -65.7% |
| 2031 | — | -67.1% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · LCTX · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-04 | D. Boral Capital | Maintains | Buy→Buy |
| 2026-03-25 | B. Riley Securities | Maintains | Buy→Buy |
| 2026-03-24 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-03-06 | D. Boral Capital | Maintains | Buy→Buy |
| 2026-02-09 | D. Boral Capital | Maintains | Buy→Buy |
| 2025-11-25 | D. Boral Capital | Maintains | Buy→Buy |
| 2025-11-24 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-08-27 | D. Boral Capital | Maintains | Buy→Buy |
| 2025-08-14 | D. Boral Capital | Maintains | Buy→Buy |
| 2025-08-05 | D. Boral Capital | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Lineage Cell Therapeutics, Inc. (LCTX) stock. Of the recent 30 rating actions, 0 were upgrades and 0 were downgrades. 5 analysts currently cover LCTX.
Analyst Recommendation Trends
LCTX analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$16M
↓ 65.5% YoY
Revenue Next Year
$10M
↓ 35.0% YoY
EPS This Year
$-0.07
EPS Next Year
$-0.09
↑ 33.3% YoY
EPS ForecastReported vs Estimated
Analysts forecast LCTX EPS of $-0.07 for the current fiscal year, based on estimates from 5 analysts. The LCTX revenue forecast is $16M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The LCTX stock forecast is supported by two independent data sources: analyst consensus ratings from 5 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus LCTX price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The LCTX short-term stock prediction for tomorrow is $1.19 (-4.08%). The LCTX stock price prediction for 2027 estimates an average of $1. The LCTX stock prediction for 2030 projects a range of $0–$0.
Lineage Cell Therapeutics, Inc. trades on AMEX under the ticker LCTX. The LCTX stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
LCTX forecast · 8 questionsAccording to 5 Wall Street analysts, the average 12-month LCTX price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $1.25.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.